Importation
Economist questions the fundamentals of importation: “It flunks a basic policy analysis.”
In this editorial published on April 26, 2019, Douglas Holtz-Eakin, economist and President of American Action Forum, questions economic truths about drug importation:
“Drug reimportation has long been the fool’s gold of health policy, and the Florida bill is no different. It flunks a basic policy analysis. But most amazing, it is drafted to raise hope, but not actually help Floridians.”
[...]Journalist on drug importation: “There is a real risk.”
In this piece published in the Washington Free Beacon on April 25, 2019, staff writer Charles Fain Lehman explores issues around Florida’s drug importation proposal. “Critics,” he notes, “fear that the actual realities of regulatory oversight—especially in the hand of an as-yet-unnamed private vendor—will simply be too challenging to manage responsibly.”
[...]Utah pharmacist and state senator: Importation raises “serious concerns about drug safety”
In this piece, which was published in The Deseret News on April 24, 2019, pharmacist and Utah State Senate Majority Leader Evan Vickers raises serious concerns about importation as a strategy to lower drug prices:
“Anyone who truly understands how drugs are sold and distributed in the U.S. knows that there are very solid technical reasons that such importation is not viable. There are also serious concerns about drug safety, since the CHS cannot guarantee origin and purity on foreign-sourced drugs.”
[...]The Bottom Line? “Importation will make it difficult to ensure that Floridians are receiving real and safe medicine.”
In this piece, which was published on the ABC affiliate WJLA’s website on April 25, 2019, political analyst Boris Epshteyn explains that “this is a risky plan that will make it difficult to ensure that Floridians are receiving real and safe medicine.”
[...]Politifact ignores the world of criminal counterfeiters
Politifact.com emailed us this week with questions about a recent ad about the dangers of attempting to import medicine from Canada. They labeled it negatively, but we noticed that they ignored certain facts while coming to their conclusion. In the interest of fairness, we’ve published below both the email from Politifact and our heavily sourced response. Judge for yourself if legislators in Florida are being naive about the risks of importation in a world with a highly evolved criminal counterfeit scheme.
[...]The case against importation: “There are simply too many channels for fake drugs to enter any importation scheme”
In this piece, which was published in the Inside Sources on April 22, 2019, Michael Graham reviews the case against drug importation: “As Scott Gottlieb said in 2016 before becoming President Trump’s FDA chief…’There are simply too many channels for fake drugs to enter any importation scheme to forgo some meaningful controls.’”
[...]Oncology Practice Managers: This “drug importation proposal that could put Floridians at risk”
In this editorial, which was published in the Palm Beach Post on April 22, 2019, Michelle Flowers writes about Florida’s history of black market cancer treatments and the danger importation poses to patients. Flowers is president of the Oncology Managers of Florida.
[...]Importation “Too Good to Be True, ” Business Columnist Warns
In this editorial, which was published in The Santa Cruz Sentinel on April 18, 2019, business columnist Jeffrey Scharf argues that importation of prescription drugs is a plan that is too good to be true.
[...]New PSM ads highlight concerns of FDA Commissioner Gottlieb about the dangers of Florida’s importation legislation
Tallahassee, FL (April 18, 2019) – Today the Partnership for Safe Medicines released new ads to run in several parts of Florida that highlight the dangers of Florida attempting to import medicine from Canada. Five different commissioners of the US Food and Drug Administration, appointed by both Republicans and Democrats, have stated that such proposals are dangerous to patients, will expose them to counterfeits, and are unlikely to reduce the price of medicine.
[...]Head of Patient Advocacy Organization Warns That Drug Importation Is Not The Solution American Patients Need
In this editorial by Terry Wilcox published in Inside Sources on April 18, 2019, Terry Wilcox, executive director of a patient advocacy organization advices federal and state representatives that allowing drug importation is not the right policy solution for America’s high prescription drug prices…
[...]